ARCHIVES

‘We Cannot Tolerate One Third Reduction In Centers. Prevention, Clinical Trials Programs’

This article is from The Cancer Letter archive.

Vol. 17 No. 36 | September 20, 1991

Download PDF Visit The Full Archive

Related Articles

Doxil/Caelyx Survival 3 Weeks Longer Than Topotecan

November 28, 2003

Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone

June 29, 2012

Sweden Approves Photofrin For Palliation Of Two Cancers.

July 28, 2000

Chabner Criticizes FDA Crackdown On Off-Label Info

June 28, 1991

Funding Opportunities: AACR Accepting Submissions for Two Dream Team Grants

September 19, 2014

Tacoma Hospital Finds Cancer DRGs Are Profitable

February 17, 1984